Table 1 Baseline characteristics of children patients with SDNS and SRNS

Gender

48

26

22

0.529

 Male

26 (54.2%)

13 (50.0%)

13 (59.1%)

 Female

22 (45.8%)

13 (50.0%)

9 (40.9%)

Age at onset of treatment (yr)

48 (9.17 ± 2.30)

26 (9.42 ± 0.21)

22 (7.64 ± 0.32)

0.126

Proteinuria before RTX treatment

0.049

 Nephrotic

24 (50.0%)

9 (34.6%)

15 (68.2%)

 Sub-nephrotic

18 (37.5%)

12 (46.2%)

6 (27.3%)

 Physiologic

6 (12.5%)

5 (19.2%)

1 (4.5%)

Renal pathology^a

0.016

 MCNS

5 (10.4%)

4 (15.4%)

1 (4.5%)

 FSGS

15 (31.2%)

4 (15.4%)

11 (50.0%)

 DMP

27 (56.2%)

18 (69.2%)

9 (41.0%)

 MGN

1 (2.1%)

0 (0.0%)

1 (4.5%)

Concomitant treatments^b

0.302

 Steroid

4 (8.3%)

1 (3.8%)

3 (13.7%)

 CNI

11 (22.9%)

6 (23.1%)

5 (22.7%)

 MMF

19 (39.6%)

13 (50.0%)

6 (27.3%)

 CNI plus MMF

14 (29.2%)

6 (23.1%)

8 (36.3%)

Early outcome (6 months after RTX)

0.005

 Complete remission

23 (47.9%)

18 (69.2%)

5 (22.7%)

 Partial remission

12 (25.0%)

3 (11.6%)

9 (41.0%)

 No response

13 (27.1%)

5 (19.2%)

8 (36.3%)

Outcome at last follow-up

0.101

 Complete remission

18 (37.5%)

13 (50.0%)

5 (22.7%)

 Partial remission

18 (37.5%)

9 (34.6%)

9 (41.0%)

 No response

12 (25.0%)

4 (15.4%)

8 (36.3%)

Existence of complication

0.196

 Yes

15 (31.2%)

10 (38.5%)

5 (22.7%)

 No

33 (68.8%)

16 (61.5%)

17 (77.3%)

Disease duration (month)^c

48 (54.54 ± 37.12)

26 (67.12 ± 39.95)

22 (39.68 ± 34.27)

0.015

Therapeutic response onset (month)^d

48 (1.55 ± 1.86)

26 (1.27 ± 1.61)

22 (1.88 ± 2.82)

0.372

The first relapse time (month)

35 (3.88 ± 4.51)

21 (4.10 ± 5.47)

14 (3.57 ± 7.12)

0.807